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 Follicular lymphoma, which represents 15% – 30% of newly diag-
nosed lymphomas, is an indolent lymphoma that is characterized 
by slow growth and a high initial response rate but relapsing and 
progressive disease ( 1 , 2 ). Most patients are diagnosed with advanced 
disease, that is, stage III or IV, and cannot be cured with currently 
available conventional therapies. New treatment modalities are 
therefore urgently needed. 
 The chimeric monoclonal antibody rituximab targeted against 
CD20, a protein that is expressed on the surface of all mature B 
cells, is active in many B-cell lymphomas that express this mole-
cule. Rituximab administered intravenously in combination with 
chemotherapy improves overall survival in patients with newly 
diagnosed and relapsed indolent lymphoma compared with che-
motherapy alone ( 3 ). The value of rituximab as maintenance 
therapy for patients who responded to induction therapy is yet to 
be determined. Phase 2 studies suggest that rituximab may improve 
response rates ( 4 , 5 ). Although clinical trials have demonstrated 
that rituximab maintenance treatment may prolong complete 
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 Amos  Cohen ,  Ofer  Shpilberg 
  Background  Follicular lymphoma is characterized by slow growth and an initially high rate of response to treatment, 
but patients typically relapse and experience progressive disease. Rituximab in combination with chemo-
therapy has been shown to improve overall survival in patients with follicular lymphoma compared with 
chemotherapy alone, but data from randomized clinical trials evaluating rituximab maintenance treatment 
in these patients are limited. We aimed to evaluate the effect of maintenance treatment with rituximab on 
the overall survival of patients with follicular lymphoma. 
  Methods  We performed a systematic review and meta-analysis of randomized controlled trials that compared ritux-
imab maintenance therapy with observation or treatment at relapse (no maintenance therapy). We 
searched  The Cochrane Library , PubMed, EMBASE, LILACS, conference proceedings, databases of ongo-
ing trials, and references of published trials. Two reviewers independently assessed the quality of the tri-
als and extracted data. Hazard ratios for time-to-event data were estimated and pooled. 
  Results  Five trials including 1143 adult patients were included in this meta-analysis. Data for 985 patients with fol-
licular lymphoma were available for the meta-analysis of overall survival. Patients treated with mainte-
nance rituximab had statistically significantly better overall survival than patients in the observation arm 
or patients treated at relapse (hazard ratio [HR] for death = 0.60, 95% confidence interval [CI] = 0.45 to 
0.79). The rate of infection-related adverse events was higher with rituximab maintenance treatment 
(HR = 1.99, 95% CI = 1.21 to 3.27). Patients with refractory or relapsed (ie, previously treated) follicular 
lymphoma had a survival benefit with maintenance rituximab therapy (HR for death = 0.58, 95% CI = 0.42 
to 0.79), whereas previously untreated patients did not (HR for death = 0.68, 95% CI = 0.37 to 1.25). 
  Conclusions  These results suggest that maintenance therapy with rituximab, either as four weekly infusions every 
6 months or as a single infusion every 2 – 3 months, should be added to standard therapy for patients with 
relapsed or refractory (ie, previously treated) follicular lymphoma after successful induction therapy. The 
higher rate of infections with rituximab therapy should be taken into consideration when making treat-
ment decisions. 
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remission and the progression-free interval, clear evidence of 
improvement in overall survival is lacking ( 6 ). Thus, rituximab 
maintenance therapy for follicular lymphoma is not recommended 
in current treatment guidelines ( http://www.nccn.org/professionals/
physician_gls/f_guidelines.asp ). 
 To date, limited data from randomized clinical trials are avail-
able to guide the use of rituximab as maintenance therapy for 
patients with follicular lymphoma who respond to induction ther-
apy, and few long-term data have been published. We performed 
a systematic review of the literature and a meta-analysis of all ran-
domized trials to evaluate the effects of rituximab maintenance 
treatment on the overall survival of patients with follicular 
lymphoma. 
 Methods 
 Data Sources 
 We searched The Cochrane Central Register of Controlled Trials, 
published in  The Cochrane Library (issue 2, 2007); PubMed (1966 to 
June 2007); EMBASE (1974 to June 2007); LILACS (1982 to June 
2007); the database of clinical trials in hematologic malignancies 
( www.hematology-studies.org ); conference proceedings of the 
American Society of Hematology (1995 – 2007), conference pro-
ceedings of the American Society of Clinical Oncology Annual 
Meeting (1995 – 2007), and proceedings of the European Hematology 
Association; and databases of ongoing and unpublished trials: 
 http://www.controlled-trials.com/ ,  http://www.clinicaltrials.gov/ct , 
 http://clinicaltrials.nci.nih.gov/ . The terms “follicular” or “indolent 
lymphoma” and similar terms and “rituximab” or “monoclonal 
antibodies” and similar terms were cross-searched. We scanned 
references of all included trials and reviews identified for additional 
studies. 
 Study Selection 
 We included all randomized controlled trials that compared ritux-
imab maintenance therapy with observation or treatment at relapse 
(no maintenance therapy) in patients with histologically confirmed 
B-cell follicular lymphoma. We included trials regardless of publi-
cation status, date of publication, and language. 
 Data Extraction and Quality Assessment 
 Two reviewers (L. Vidal and A. Gafter-Gvili) independently 
extracted data regarding case definitions, characteristics of patients, 
and outcomes from included trials. In the event of disagreement 
between the two reviewers regarding any of the above, a third 
reviewer (O. Shpilberg) extracted the data. Data extraction was 
discussed, and decisions were documented. 
 We contacted the ﬁ rst or corresponding author of each included 
trial and the researchers who were active in the ﬁ eld to obtain 
information on unpublished trials or additional information on the 
published trials. Two reviewers (L. Vidal and A. Gafter-Gvili) 
independently assessed the trials for methodological quality. 
Allocation concealment, generation of the allocation sequence, and 
blinding were individually assessed and graded as adequate, 
unclear, or inadequate ( 7 ). We also collected data on exclusions 
after randomization and whether the primary analysis was per-
formed according to the intention-to-treat principle or per 
protocol. 
 Outcome Measures 
 The primary outcome was overall survival [as defined in ( 8 , 9 )]. 
Secondary outcomes included event-free interval, progression-free 
interval, and adverse events. 
 Data Synthesis and Statistical Analysis 
 Hazard ratios (HRs) and variances for time-to-event outcomes 
were estimated as described by Parmar et al. ( 10 , 11 ) and pooled 
according to Peto ’ s method (Review Manager [RevMan], version 
4.2 for Windows; The Cochrane Collaboration, Oxford, UK). A 
hazard ratio less than 1.0 was in favor of rituximab maintenance 
therapy. Relative risks (RRs) and 95% confidence intervals (CIs) 
for dichotomous data were estimated using the Mantel – Haenszel 
method. We used a fixed effect model, and when possible, we per-
formed a sensitivity analysis by repeating the above analysis using a 
random effects model (the DerSimonian and Laird method) ( 12 ). 
 We assessed heterogeneity of trial results by the chi test of 
heterogeneity and the  I 2 statistic of inconsistency. Statistically sig-
niﬁ cant heterogeneity was deﬁ ned as  P less than .1 or an  I 2 statistic 
greater than 50% ( 13 ). Potential sources of heterogeneity were 
explored through stratifying by type of induction therapy (chemo-
therapy, rituximab, chemotherapy + rituximab), rituximab sched-
ule (one infusion every 2 months; four weekly infusions every 
6 months), allocation concealment, blinding, and size of studies. 
All statistical tests were two-sided. 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 Most follicular lymphoma patients respond to initial treatment, but 
they often experience disease relapse. 
 Study design 
 Meta-analysis of randomized controlled trials of patients with fol-
licular lymphoma comparing rituximab maintenance therapy with 
observation or treatment at relapse. 
 Contributions 
 Maintenance rituximab therapy improved overall survival of follic-
ular lymphoma patients compared with observation or treatment 
at relapse but led to higher rates of infection-related adverse 
events. Previously treated patients had improved survival with 
maintenance rituximab therapy, but previously untreated patients 
did not. 
 Implications 
 Maintenance therapy with rituximab improves survival in patients 
who have previously been treated for follicular lymphoma, but the 
high rate of infection should be considered when making treatment 
decisions. 
 Limitations 
 Three of the five trials included in the meta-analysis were termi-
nated before the planned endpoint of the study, so longer follow-up 
was not possible and treatment effects may have been 
overestimated. 
 From the Editors 
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 Publication Bias and Small Studies ’ Effect 
 We examined the funnel plot for overall survival to estimate the 
effect of small study size (ie, publication bias). 
 Results 
 Description of Trials 
 The literature search identified 265 trials, of which 27 were consid-
ered potentially relevant. Additional trials were identified by search-
ing conference proceedings and electronic resources of ongoing 
trials.  Figure 1 illustrates the process of study selection. Reasons for 
exclusion are detailed in  Supplementary Table 1 (available online). 
Five trials that were performed between 1998 and 2004 fulfilled the 
inclusion criteria ( 6 , 14 – 18 ). Two of the included abstracts ( 17 , 18 ) 
reported the outcomes of different subsets of patients from the same 
trial (Eastern Cooperative Oncology Group study E1496). 
 Patient Characteristics.  All trials included patients with indolent 
lymphoma. Three trials included patients with follicular lym-
phoma of any grade ( 6 , 14 , 16 ). Two trials included patients with 
follicular lymphoma grade 1 or 2 or with small lymphocytic 
lymphoma ( 15 , 17 , 18 ). One trial ( 15 ) also included patients with 
mantle cell lymphoma ( Table 1 ) ( 16 ). The minimal requirement 
for inclusion in the original trials was either stable disease (three 
trials) ( 6 , 15 , 17 , 18 ) or partial remission (two trials) ( 14 , 16 ) after 
induction therapy. Most patients (67%) had relapsed or refractory 
disease. One trial ( 6 ) included patients with relapsed disease and 
chemotherapy-naive patients. One trial included untreated patients 
only ( 17 , 18 ). Other common exclusion criteria of the original trials 
were poor performance status, active infection, symptomatic cen-
tral nervous system disease, and a history of serious medical condi-
tions. The percentage of patients with stage III or IV follicular 
lymphoma ranged from 85% to 100% and was not reported in one 
trial ( 15 ). In that trial, 88% of patients had low or low-to-intermediate 
international prognostic index scores. The median follow-up ranged 
from 26 to 41 months. 
 Trial Design.  In three trials ( 14 , 16 – 18 ), patients were randomly 
assigned to a type of induction therapy and subsequently underwent 
a second random assignment to maintenance therapy or observation. 
In the other two trials ( 6 , 15 ), all patients were treated with the same 
induction therapy and were subsequently randomly assigned to 
maintenance therapy or observation. 
 Induction Therapy and Maintenance Protocol.  Induction ther-
apy included three options: chemotherapy alone ( 17 , 18 ), chemo-
therapy with or without rituximab ( 14 , 16 ), and rituximab alone 
( 6 , 15 ). Prior rituximab treatment was not allowed in two trials 
( 6 , 15 ). In one trial ( 15 ), patients in the control group received 
rituximab upon progression of follicular lymphoma; in the other 
four trials, patients in the control group were observed without 
rituximab treatment. In all trials, a dose of rituximab consisted of 375 
mg/m 2 /d and was not adjusted according to blood concentration. 
The treatment schedule differed among the trials: In three trials 
( 15 – 18 ), rituximab was administered weekly for 4 consecutive 
weeks (four doses) every 6 months, and in two trials ( 6 , 14 ), a single 
infusion of rituximab was administered every 2 – 3 months. The 
duration of treatment also varied, from 8 – 9 months ( 6 , 16 ) to 
2 years ( 14 , 15 , 17 , 18 ). 
 Quality of Trials.  Allocation concealment was reported as ade-
quate in three trials ( 6 , 15 , 16 ) and was not reported in the other two 
trials. None of the trials were conducted in a blinded fashion. An 
intention-to-treat analysis (ie, all randomly assigned patients were 
included for assessment of the primary outcome) was performed in 
two trials ( 14 , 15 ). The rate of dropout was less than 10% in four 
trials ( 6 , 14 – 16 ). The quality of allocation concealment and of gen-
eration of randomization sequence and the funding sources of the 
trials are described in detail in  Table 1 . 
 Overall Survival 
 All five trials (985 patients) were eligible for the meta-analysis of 
overall survival. The numbers of randomly assigned and analyzed 
patients in each included trial are described in  Table 1 . Patients 
who were treated with rituximab maintenance therapy had statisti-
cally significantly better overall survival than patients in the con-
trol group (HR of death = 0.60, 95% CI = 0.45 to 0.79) ( Figure 2 ). 
No statistically significant heterogeneity was observed for overall 
survival. The funnel plot of the primary outcome did not support 
a publication bias ( Figure 2 ). 
 Figure 1 .  Flow diagram of publica-
tions identiﬁ ed for study and 
exclusions. 
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 Sensitivity Analysis.  One published abstract was excluded in the 
sensitivity analysis of overall survival, as recommended by its 
authors ( 17 ). Excluding these data did not change the pooled over-
all survival results. 
 In addition, overall survival in the trials was analyzed separately 
according to the following variables: type of control arm (observa-
tion vs treatment at progression), maintenance schedule, previous 
treatment, and rituximab induction therapy. 
 Four trials compared rituximab maintenance therapy with 
observation (HR of death = 0.53, 95% CI = 0.38 to 0.73) ( 6 , 14 ,
 16 – 18 ), and one trial compared rituximab maintenance therapy 
with rituximab treatment on progression of lymphoma (HR of 
death = 0.86, 95% CI = 0.49 to 1.49) ( 15 ). However, it is important 
to note that the latter trial lacked statistical power to show an effect 
of rituximab maintenance, if such an effect existed. 
 The type of rituximab maintenance schedule had no effect on 
overall survival. Treatment with a single infusion of rituximab 
every 2 – 3 months improved overall survival (HR of death = 0.51, 
95% CI = 0.34 to 0.75), but weekly treatment with rituximab for 
4 weeks every 6 months resulted in only borderline beneﬁ t (HR of 
death = 0.70, 95% CI = 0.47 to 1.04; three trials) ( 15 – 18 ) compared 
with observation or rituximab at progression. 
 Patients with refractory or relapsed follicular lymphoma had a 
clear survival beneﬁ t with maintenance rituximab therapy com-
pared with patients who underwent observation (HR of death = 
0.58, 95% CI = 0.42 to 0.79; four trials) ( 6 , 14 – 16 ) ( Figure 3 ). 
However, among patients who were not treated in the past, the 
beneﬁ t was not statistically signiﬁ cant (HR of death = 0.68, 95% 
CI = 0.37 to 1.25; two trials) ( 6 , 17 , 18 ) ( Figure 3 ). 
 Two trials included patients whose induction therapy consisted 
of single-agent rituximab with no chemotherapy ( 6 , 15 ). One trial 
( 15 ) included mainly patients with low tumor burden, and in that 
trial, rituximab maintenance was compared with rituximab at pro-
gression. No clear statistically signiﬁ cant beneﬁ t with rituximab 
maintenance was demonstrated in the meta-analysis of these two 
trials (HR of death = 0.67, 95% CI = 0.45 to 1.01; 240 patients). 
 The quality of allocation concealment (adequate or not 
reported) had no effect on the outcomes. The beneﬁ t of rituximab 
maintenance was shown in all trials of adequate quality (HR of 
death = 0.64, 95% CI = 0.44 to 0.93; three trials) ( 6 , 15 , 16 ). 
 Almost all patients had stage III or IV, relapsed or refractory 
disease. Unfortunately, there was not enough data to analyze over-
all survival according to age, follicular lymphoma international 
prognostic index score at baseline, performance status, grade of 
lymphoma, or chemotherapy regimen in induction therapy. 
 Secondary Outcomes 
 The pooled hazard ratios of event- and progression-free intervals 
were 0.46 (95% CI = 0.37 to 0.57; three trials, 589 patients) 
( 6 , 14 , 16 ) and 0.53 (95% CI = 0.42 to 0.66; two trials, 454 patients) 
( 6 , 17 , 18 ), respectively. Bcl-2 conversion rate, considered a prog-
nostic factor in follicular lymphoma, and the effect of rituximab 
 Figure 3 .  Pooled HRs of overall 
survival of patients with refrac-
tory or relapsed follicular lym-
phoma and of untreated patients 
with follicular lymphoma.  Black 
squares represent the point esti-
mate,  their sizes represent their 
weight in the pooled analysis, 
and the  horizontal bars represent 
the 95% CI. The  black diamond at 
the bottom represents the pooled 
point estimate. HR = hazard ratio 
for death; CI = conﬁ dence inter-
val; MR = maintenance therapy 
with rituximab. 
 Figure 2 .  Pooled estimates of overall sur-
vival with rituximab maintenance therapy 
for patients with follicular lymphoma com-
pared with observation and rituximab at 
disease progression.  Black squares repre-
sent the point estimate,  their sizes repre-
sent their weight in the pooled analysis, 
and the  horizontal bars represent the 95% 
CI. The  black diamond at the bottom repre-
sents the pooled point estimate. HR = haz-
ard ratio for death; CI = conﬁ dence interval; 
MR = maintenance therapy with rituximab. 
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maintenance treatment on quality of life were not reported for the 
included trials. 
 Adverse Events 
 The rate of grade 3 or 4 adverse events was reported in three trials 
( 6 , 14 , 16 ) and was higher in the rituximab maintenance therapy 
arm than in the observation arm (RR = 1.52, 95% CI = 1.00 to 
2.30). Specifically, patients who underwent rituximab maintenance 
therapy had more infection-related adverse events than patients in 
the observation arm (RR = 1.99, 95% CI = 1.21 to 3.27) ( Figure 4 ). 
When only grade 3 or 4 infection-related adverse events were 
included in the analysis, this effect was even more pronounced (RR = 
2.90, 95% CI = 1.24 to 6.76). In one trial ( 14 ), mainly infections 
of the upper respiratory tract occurred, and hospitalization was 
required for all grade 3 or 4 infection-related adverse events. The 
rate of adverse events requiring discontinuation of therapy was 
reported in one trial ( 14 ) and was higher in the group that received 
rituximab maintenance therapy. 
 Discussion 
 This meta-analysis demonstrates for the first time, to our knowl-
edge, that rituximab maintenance therapy improves overall sur-
vival and disease control compared with observation in patients 
with refractory or relapsed follicular lymphoma who responded to 
induction therapy. This effect on overall survival was statistically 
significant, despite higher rates of severe adverse events, and espe-
cially treatment-related infections. Based on data from one trial, 
no difference in overall survival was observed when rituximab 
maintenance was compared with retreatment with rituximab at 
disease progression. 
 Despite different kinds of induction therapy and maintenance 
schedule, the point estimate for all pooled analyses favored ritux-
imab maintenance therapy. This clinical heterogeneity in the 
absence of statistical heterogeneity supports the robustness of our 
results. 
 However, rituximab maintenance therapy has its drawbacks. 
The most common adverse events were infections, some life 
threatening. Rituximab may cause immunosuppression through 
several mechanisms, as delayed-onset cytopenia, particularly neu-
tropenia ( 19 ), and hypogammaglobulinemia ( 20 – 23 ). Both cytope-
nia and hypogammaglobulinemia have been reported to various 
degrees among patients who were treated with rituximab for vari-
ous reasons. These effects might be of even greater clinical signiﬁ -
cance when rituximab is administered for a longer period, as it is 
in maintenance therapy ( 24 ). In addition to the clinical effects of 
prolonged treatment, the ﬁ nancial costs of this rituximab mainte-
nance therapy should be taken into consideration. 
 Several limitations of our analysis merit consideration. The 
included studies differed in their induction therapy: in two trials, ritux-
imab monotherapy was given and the chemotherapy regimens varied 
among the other trials. In the trial by Hochster et al. ( 18 ), patients who 
  
 Figure 4 .  Infection-related adverse events in patients with follicular lymphoma treated with rituximab maintenance compared with observation. 
 Black squares represent the point estimate,  their sizes represent their weight in the pooled analysis, and the  horizontal bars represent the 95% CI. 
The  black diamond at the bottom represents the pooled point estimate. CI = conﬁ dence interval; MR = maintenance therapy with rituximab. 
 Table 2 .  Description of ongoing trials of rituximab maintenance therapy * 
 Investigator/protocol chair 
(reference), ClinicalTrials.gov web site Patients Induction Intervention 
 Williams/Kahl ( 28 ),  http://clinicaltrials.
 gov/ct2/show/NCT00075946 
Patients with low tumor burden, 
 stage III – IV indolent lymphoma
Rituximab Arm I: rituximab upon disease 
 progression 
 Arm II: MR 
 Taverna ( 29 ),  http://clinicaltrials.gov/
 ct2/show/NCT00227695 
Patients with untreated or 
 resistant or relapsed FL
Rituximab Arm I: MR for 8 mo 
 Arm II: MR up to 5 y 
 Pettengell and Linch ( 30 ),  http://
 clinicaltrials.gov/ct2/show/
 NCT00005589 
Patients with relapsed FL Chemotherapy + 
 HSCT + in vivo 
 rituximab purging
Arm I: MR 
 Arm II: observation 
 Ardeshna ( 31 ),  http://clinicaltrials.gov/
 ct2/show/NCT00112931 
Patients with newly diagnosed 
 stage II – IV FL with no symptoms
See Intervention Arm I: observation 
 Arm II: induction rituximab 
 Arm III: induction rituximab and MR 
 Salles ( 32 ),  http://clinicaltrials.gov/
 show/NCT00140582 
Patients with untreated FL 
 requiring treatment
Rituximab with 
 chemotherapy
Arm I: MR 
 Arm II: no treatment 
 *  FL = follicular lymphoma; HSCT = hematopoietic stem cell transplantation; MR = rituximab maintenance therapy. 
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were treated with ﬂ udarabine and cyclophosphamide had a worse 
outcome with maintenance therapy than those who received cyclo-
phosphamide, vincristine, and prednisone during induction therapy, 
suggesting a possible interaction between the type of chemotherapy 
used in induction therapy and the effect of rituximab maintenance 
therapy. In addition, because these trials were conducted before ritux-
imab was considered part of standard therapy in patients with follicu-
lar lymphoma, some of the patients did not receive rituximab during 
induction therapy. The maintenance schedule also varied — weekly 
infusions for 4 consecutive weeks every 6 months or a single infusion 
of rituximab every 2 – 3 months. Again, it should be noted that these 
differences in rituximab schedule did not change the results. 
 Three trials were terminated earlier than initially planned after 
the stopping criteria were met ( 14 , 16 – 18 ). Statistical theories and the 
results of a systematic review of randomized trials that were stopped 
early for apparent beneﬁ t suggest that the early stopping of trials 
leads to a systematic overestimation of the treatment effects ( 25 , 26 ). 
The scientiﬁ c validity of trials that are stopped early is further 
compromised when trials yield inconclusive data about outcomes 
that did not inﬂ uence trial termination, in this case overall survival. 
 A recently published systematic review on rituximab in non –
 Hodgkin lymphoma favors the use of maintenance rituximab for 
patients with follicular lymphoma who respond to treatment with 
combination chemotherapy and/or rituximab ( 27 ). However, these 
recommendations were not based on overall survival and did not 
include a statistical summary of pooled outcomes. 
 Our results suggest that rituximab maintenance therapy for up 
to 2 years, either as four weekly infusions every 6 months or as a 
single infusion every 2 – 3 months, should be added to standard 
therapy of patients with relapsed or refractory follicular lymphoma 
after successful induction treatment. 
 Open questions still exist regarding the effect of rituximab 
maintenance on the outcome of patients with follicular lymphoma, 
some of which are currently being evaluated in randomized clinical 
trials (Table 2). These questions include the effects of rituximab 
maintenance therapy compared with rituximab at disease progres-
sion, effects of rituximab maintenance therapy in previously 
untreated patients with advanced follicular lymphoma, effects of 
rituximab maintenance therapy in patients with follicular lym-
phoma following rituximab and chemotherapy induction, the 
optimal duration of rituximab maintenance therapy, and the opti-
mal schedule of rituximab maintenance. Finally, both randomized 
controlled trials and observational studies should have longer 
follow-up to assess the long-term toxicity of rituximab. 
 References 
  1.  Ardeshna  KM ,  Smith  P ,  Norton  A , et al.  Long-term effect of a watch and 
wait policy versus immediate systemic treatment for asymptomatic 
advanced-stage non-Hodgkin lymphoma: a randomised controlled trial . 
 Lancet .  2003 ; 362 ( 9383 ): 516 – 522 . 
  2.  Horning  SJ .  Natural history of and therapy for the indolent non-Hodgkin’s 
lymphomas .  Semin Oncol .  1993 ; 20 ( 5 suppl 5 ): 75 – 88 . 
  3.  Schulz  H ,  Bohlius  J ,  Skoetz  N , et al .  Chemotherapy plus rituximab versus 
chemotherapy alone for B-cell non-Hodgkin’s lymphoma .  Cochrane 
Database Syst Rev.  2007(4):CD003805 . 
  4.  Gordan  LN ,  Grow  WB ,  Pusateri  A ,  Douglas  V ,  Mendenhall  NP ,  Lynch 
 JW .  Phase II trial of individualized rituximab dosing for patients with 
CD20-positive lymphoproliferative disorders .  J Clin Oncol .  2005 ; 23 ( 6 ): 
1096 – 1102 . 
  5.  Hainsworth  JD .  Rituximab as ﬁ rst-line and maintenance therapy for 
patients with indolent non-Hodgkin’s lymphoma: interim follow-up of a 
multicenter phase II trial .  Semin Oncol .  2002 ; 29 ( 1 suppl 2 ): 25 – 29 . 
  6.  Ghielmini  M ,  Schmitz  SF ,  Cogliatti  SB , et al .  Prolonged treatment with 
rituximab in patients with follicular lymphoma signiﬁ cantly increases 
event-free survival and response duration compared with the standard 
weekly x 4 schedule .  Blood .  2004 ; 103 ( 12 ): 4416 – 4423 . 
  7.  Schulz  KF ,  Chalmers  I ,  Hayes  RJ ,  Altman  DG .  Empirical evidence of bias. 
Dimensions of methodological quality associated with estimates of treat-
ment effects in controlled trials .  JAMA .  1995 ; 273 ( 5 ): 408 – 412 . 
  8.  Cheson  BD ,  Horning  SJ ,  Coifﬁ er  B , et al .  Report of an international work-
shop to standardize response criteria for non-Hodgkin’s lymphomas. NCI 
Sponsored International Working Group .  J Clin Oncol .  1999 ; 17 ( 4 ): 1244 . 
  9.  Cheson  BD ,  Pﬁ stner  B ,  Juweid  ME , et al .  Revised response criteria for 
malignant lymphoma .  J Clin Oncol .  2007 ; 25 ( 5 ): 579 – 586 . 
  10.  Parmar  MK ,  Torri  V ,  Stewart  L .  Extracting summary statistics to perform 
meta-analyses of the published literature for survival endpoints .  Stat Med . 
 1998 ; 17 ( 24 ): 2815 – 2834 . 
  11.  Tierney  JF ,  Stewart  LA ,  Ghersi  D ,  Burdett  S ,  Sydes  MR .  Practical meth-
ods for incorporating summary time-to-event data into meta-analysis . 
 Trials .  2007 ; 8 : 16 . 
  12.  DerSimonian  R ,  Laird  N .  Meta-analysis in clinical trials .  Control Clin 
Trials .  1986 ; 7 ( 3 ): 177 – 188 . 
  13.  Higgins  JP ,  Thompson  SG ,  Deeks  JJ ,  Altman  DG .  Measuring inconsis-
tency in meta-analyses .  BMJ .  2003 ; 327 ( 7414 ): 557 – 560 . 
  14.  van Oers  MH ,  Klasa  R ,  Marcus  RE , et al .  Rituximab maintenance 
improves clinical outcome of relapsed/resistant follicular non-Hodgkin 
lymphoma in patients both with and without rituximab during induction: 
results of a prospective randomized phase 3 intergroup trial .  Blood .  2006 ;
 108 ( 10 ): 3295 – 3301 . 
  15.  Hainsworth  JD ,  Litchy  S ,  Shaffer  DW ,  Lackey  VL ,  Grimaldi  M ,  Greco 
 FA .  Maximizing therapeutic beneﬁ t of rituximab: maintenance therapy 
versus re-treatment at progression in patients with indolent non-Hodgkin’s 
lymphoma — a randomized phase II trial of the Minnie Pearl Cancer 
Research Network .  J Clin Oncol .  2005 ; 23 ( 6 ): 1088 – 1095 . 
  16.  Forstpointner  R ,  Unterhalt  M ,  Dreyling  M , et al .  Maintenance therapy 
with rituximab leads to a signiﬁ cant prolongation of response duration 
after salvage therapy with a combination of rituximab, ﬂ udarabine, cyclo-
phosphamide, and mitoxantrone (R-FCM) in patients with recurring and 
refractory follicular and mantle cell lymphomas: results of a prospective 
randomized study of the German Low Grade Lymphoma Study Group 
(GLSG) .  Blood .  2006 ; 108 ( 13 ): 4003 – 4008 . 
  17.  Hochster  H ,  Weller  E ,  Gascoyne  R , et al .  Maintenance rituximab after CVP 
results in superior clinical outcome in advanced follicular lymphoma (FL): 
results of the E1496 Phase III Trial from the Eastern Cooperative Oncology 
Group and the Cancer and Leukemia Group B .  Blood .  2005 ; 106 : 349 . 
  18.  Hochster  H ,  Weller  E ,  Gascoyne  R , et al .  Cyclophosphamide and ﬂ udara-
bine (CF) in advanced indolent lymphoma: results from the ECOG/
CALGB intergroup E1496 trial .  J Clin Oncol.  (ASCO Annual Meeting 
Proceedings Part I) .  2007 ; 25 ( 18S ): 8004 . 
  19.  Cattaneo  C ,  Spedini  P ,  Casari  S , et al .  Delayed-onset peripheral blood 
cytopenia after rituximab: frequency and risk factor assessment in a con-
secutive series of 77 treatments .  Leuk Lymphoma .  2006 ; 47 ( 6 ): 1013 – 1017 . 
  20.  Castagnola  E ,  Dallorso  S ,  Faraci  M , et al .  Long-lasting hypogammaglobu-
linemia following rituximab administration for Epstein-Barr virus-related 
post-transplant lymphoproliferative disease preemptive therapy . 
 J Hematother Stem Cell Res .  2003 ; 12 ( 1 ): 9 – 10 . 
  21.  Lim  SH ,  Esler  WV ,  Zhang  Y , et al .  B-cell depletion for 2 years after 
autologous stem cell transplant for NHL induces prolonged hypogam-
maglobulinemia beyond the rituximab maintenance period .  Leuk 
Lymphoma .  2008 ; 49 ( 1 ): 152 – 153 . 
  22.  Lim  SH ,  Zhang  Y ,  Wang  Z , et al .  Maintenance rituximab after autologous 
stem cell transplant for high-risk B-cell lymphoma induces prolonged and 
severe hypogammaglobulinemia .  Bone Marrow Transplant .  2005 ; 35 ( 2 ): 
207 – 208 . 
  23.  Shortt  J ,  Spencer  A .  Adjuvant rituximab causes prolonged hypogamma-
globulinaemia following autologous stem cell transplant for non-Hodgkin’s 
lymphoma .  Bone Marrow Transplant .  2006 ; 38 ( 6 ): 433 – 436 . 
jnci.oxfordjournals.org   JNCI | Articles 255
  24.  Filanovsky  K ,  Shvidel  L ,  Shtalrid  M ,  Haran  M ,  Duek  A ,  Berrebi  A . 
 Predictive factors to hypogammaglobulinemia and non-neutropenic infec-
tion complications after rituximab/chemotherapy treatment .  Blood . 
 2007 ; 110 ( 11 ): 1288 . 
  25.  Montori  VM ,  Devereaux  PJ ,  Adhikari  NK , et al .  Randomized trials stopped 
early for beneﬁ t: a systematic review .  JAMA .  2005 ; 294 ( 17 ): 2203 – 2209 . 
  26.  Bassler  D ,  Ferreira-Gonzalez  I ,  Briel  M , et al .  Systematic reviewers 
neglect bias that results from trials stopped early for beneﬁ t .  J Clin 
Epidemiol .  2007 ; 60 ( 9 ): 869 – 873 . 
  27.  Cheung  MC ,  Haynes  AE ,  Meyer  RM ,  Stevens  A ,  Imrie  KR .  Rituximab in 
lymphoma: a systematic review and consensus practice guideline from 
Cancer Care Ontario .  Cancer Treat Rev.  2007 ; 33 ( 2 ): 161 – 176 . 
  28.  Available at:  http://clinicaltrials.gov/ct2/show/NCT00075946 . Accessed 
January 5, 2008. 
  29.  Available at:  http://clinicaltrials.gov/ct2/show/NCT00227695 . Accessed 
January 5, 2008 . 
  30.  Available at:  http://clinicaltrials.gov/ct2/show/NCT00005589 . Accessed 
January 5, 2008 . 
  31.  Available at:  http://clinicaltrials.gov/ct2/show/NCT00112931 . Accessed 
January 5, 2008 . 
  32.  Available at:  http://clinicaltrials.gov/show/NCT00140582 . Accessed 
January 5, 2008 . 
 Funding 
 No funding was received for this study. Dr M.G. has given consultancy ser-
vices for and received research funding from Roche, the maker of rituximab. 
Dr M.D. received research funding for investigator-initiated trials and speaker 
honorarium from Roche. 
 Notes 
 Roche had no role in the study design, the collection and analysis of the 
data, the interpretation of the results, the preparation of the manuscript, 
the decision to submit the manuscript for publication, or in the funding of 
the study. 
 The study was conducted as part of the Cochrane Collaboration, and its 
protocol is available in  The Cochrane Library . 
 Manuscript received  May  12 ,  2008 ; revised  October  31 ,  2008 ; accepted 
 November  21 ,  2008 . 
